Couldn't agree more.
Today's volume dried quickly, share price held up well.
Last year's spike from 1.6c to 9.4c on huge volume merely based on an article, nothing from the company fundamentals.
The trial results are fundamental, could re-rate quickly as it has huge potential if commercialised.
All imo.
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-543
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.7¢ |
Change
-0.002(2.25%) |
Mkt cap ! $78.43M | |||
| Open | High | Low | Value | Volume |
| 9.0¢ | 9.0¢ | 8.5¢ | $84.69K | 975.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | 8.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.3¢ | 200000 | 2 |
View Market Depth
| Last trade - 15.18pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.8¢ |
Change
-0.002 ( 1.12 %) |
||||
| Open | High | Low | Volume | ||
| 8.7¢ | 8.8¢ | 8.5¢ | 159060 | ||
| Last updated 15.17pm 05/06/2024 ? | |||||
| PER (ASX) Chart |